Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review.
about
Disulfiram for alcohol use disorderNicotine receptor partial agonists for alcohol dependenceNicotine receptor partial agonists for alcohol dependenceThe relationship of appetitive, reproductive and posterior pituitary hormones to alcoholism and craving in humansRole of appetite-regulating peptides in the pathophysiology of addiction: implications for pharmacotherapyEmerging concepts in alcoholic hepatitisService delivery and pharmacotherapy for alcohol use disorder in the era of health reform: Data from a national sample of treatment organizationsThe CRF system and social behavior: a review.Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism.Different contributions of dopamine D1 and D2 receptor activity to alcohol potentiation of brain stimulation reward in C57BL/6J and DBA/2J mice.A pilot examination of the genome-wide DNA methylation signatures of subjects entering and exiting short-term alcohol dependence treatment programs.Pharmacotherapy for alcoholic patients with alcoholic liver diseaseIntravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigationSerotonin-2C receptor agonists decrease potassium-stimulated GABA release in the nucleus accumbens.A single dose of kudzu extract reduces alcohol consumption in a binge drinking paradigm.Recruitment techniques for alcohol pharmacotherapy clinical trials: A cost-benefit analysisCaenorhabditis elegans as a Model to Study the Molecular and Genetic Mechanisms of Drug Addiction.Management of alcohol dependence in patients with liver disease.Use of novel technology-based techniques to improve alcohol-related outcomes in clinical trials.The mean and the individual: integrating variable-centered and person-centered analyses of cognitive recovery in patients with substance use disorders.Combined pharmacotherapies for the management of alcoholism: rationale and evidence to date.Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease.Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?Leptin levels are reduced by intravenous ghrelin administration and correlated with cue-induced alcohol craving.Histamine h3 receptor: a novel therapeutic target in alcohol dependence?A Call to Action: Alcohol Interventions in HIV-Infected Patients.Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease.Efficacy of D-penicillamine, a sequestering acetaldehyde agent, in the prevention of alcohol relapse-like drinking in rats.Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin.Differential effects of baclofen and oxytocin on the increased ethanol consumption following chronic psychosocial stress in mice.In Vitro Functional Characterization of GET73 as Possible Negative Allosteric Modulator of Metabotropic Glutamate Receptor 5.
P2860
Q24198009-32453322-272A-4C71-B665-CD49C1987C7AQ24234860-9D762DA5-78DC-44AB-8CC7-68FD958CFF13Q26472086-06EAFF48-AFD0-4709-883B-1C8FE146EC24Q26992207-2872327C-5BD4-4F25-8F03-164B235DEB43Q28109507-E6A96141-0AC2-4349-B381-9CF2FDA1C618Q30234425-D3C8510A-35AA-4785-AE4A-A07C42CEF539Q30373948-7C131E27-A68B-40BF-BA63-E4D568BFC4E7Q30453661-53472264-2024-4F87-A8B9-C3D7B76A56B0Q33591091-F2008B6A-2A5B-4B8B-9C10-E58A0C197C40Q33944003-99D2FAF6-29FA-4D2A-9316-4CAEA3BDA237Q34212648-326BA5BB-01D0-464A-956B-157DAEC0F34DQ34223054-1D19A6CB-F178-4E20-ABFE-987684E77579Q34250821-A12463EA-B50D-4046-B406-4EC9DB6AC494Q34765276-8DE38C48-EE59-49D9-9304-C063195C11A9Q35876092-C52ED06A-11FC-4B51-92DC-2990EFEAB2C9Q36440595-20D441C7-BA0F-46EC-A63D-1B62267AB876Q36807410-964E5DC1-9F30-480F-B215-935B2B4DF208Q37165425-2F4AAE7C-683C-47A5-8657-514BCD59C4D0Q37276159-27651155-089D-4331-882B-B19B7F3CC5B3Q37410052-4E38DDAA-CFBB-44C0-B038-6125DC11C755Q38185313-FD6BB763-BEC3-443E-A3B3-D807026EF140Q39041281-2AD0822E-B318-4B57-82B2-133F6DEEA534Q39090733-9A291E17-FB88-407F-8125-CD9E57FF6CB5Q41270245-BA9CD8F4-4605-4AAD-98C8-723C9425978CQ41883032-946F0080-B723-4838-9DF7-9F32A68BE5F2Q42542870-0B6D2739-1FA6-4F4C-AB6A-C4C04FFCB138Q46518690-F42A25D6-C0E7-410F-A9F0-5DDEBC360B88Q46846272-78E61915-1458-44B8-B188-92A16F584A10Q47851680-CFC9A755-84B0-43B1-B52E-41EA4757D01BQ52301706-A46B80C3-D318-4E9E-9A3B-B2B10DEF3E2FQ52318135-883B5480-D03E-4F0C-931C-9F3D3ADF84B6
P2860
Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current and promising pharmaco ...... alcohol dependence: a review.
@en
Current and promising pharmaco ...... alcohol dependence: a review.
@nl
type
label
Current and promising pharmaco ...... alcohol dependence: a review.
@en
Current and promising pharmaco ...... alcohol dependence: a review.
@nl
prefLabel
Current and promising pharmaco ...... alcohol dependence: a review.
@en
Current and promising pharmaco ...... alcohol dependence: a review.
@nl
P2093
P1476
Current and promising pharmaco ...... alcohol dependence: a review.
@en
P2093
George A Kenna
Lorenzo Leggio
Robert M Swift
Steven Edwards
P304
P356
10.2174/138161211796150765
P577
2011-01-01T00:00:00Z